Latest peptide research, scientific breakthroughs, and academic discoveries
AI-designed peptides have entered clinical development with diffusion models achieving 34% experimental hit rates against undruggable targets. Machine learning is compressing peptide discovery timelines from 18 months to 6 weeks, but synthesizability and drug-likeness remain unsolved challenges.
Peptide-drug conjugates combine tumor-homing peptides with cytotoxic payloads for targeted cancer therapy. With 23 clinical programs and 38% response rates in ADC-resistant patients, PDCs offer superior penetration and lower manufacturing costs than antibody-based alternatives.
Macrocyclic peptides are breaching the 85% of human proteins once considered undruggable. With 47 candidates in clinical development and AI-driven design achieving 34% hit rates, the modality is entering the therapeutic mainstream.
Antimicrobial peptides are finally moving from academic curiosity to clinical reality. With AMR on the rise, AMPs offer a fundamentally different mechanism that bacteria struggle to resist.
GLP-1 agonists are moving beyond diabetes and obesity into cardiovascular, neurodegenerative, and addiction indications. Here’s what the peptide science tells us about the next decade.